Paul Stoffels, company group chairman for Global R&D Pharmaceuticals at Johnson & Johnson, has a guest blog at CNBC about how "recent advances in science, genomics technologies, biomarkers, and drug development" have coalesced to offer the potential for personalized medicine. Using HIV drug development as an example, Stoffels makes the case that relying on diagnostic expertise throughout the process led not only to more targeted treatment, but also helped the pharma make better drugs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.